Kyowa Hakko Kirin Co., Ltd., formerly KYOWA HAKKO KOGYO CO., LTD., is a Japan-based manufacturer that has five business segments. The Medical Product segment is engaged in the manufacture, sale and promotion of medical products for hospital use, as well as the provision of technologies for antibody drug creation, the development of candidate substances for new drugs and the supply of clinical test reagents. The Biochemical segment offers medical and industrial materials, mainly amino and nucleic acids, as well as healthcare items and products for agriculture and fishery uses. It also designs and constructs facilities. The Chemical Product segment provides solvents, plasticizers, materials for plasticizers and functional products, among others. Its Food segment supplies seasonings, materials for confectionery and bread making, processed food products and others. The Others segment is involved in the wholesale and distribution businesses, as well as the provision of industrial alcohol.

Chesapeake PERL was founded in 2000. Chesapeake PERL calls a "mini bioreactor" to produce proteins. Using its PERLXpress technology platform, the company mass produces antibodies, enzymes, viral antigens, and other proteins in whole insect larvae. It sells its custom protein development services, as well as some research reagents, to biotech concerns, including drug and diagnostics companies, biotech instrument makers, agricultural companies, and makers of industrial enzymes. It has also received federal grants from the NIH, the US Army, and the US Department of Energy.

Bactolac Pharmaceutical (formerly Advanced Nutraceuticals) makes private-label vitamins, minerals, herbs, and other over-the-counter nutritional supplement products. The company's encapsulated and tablet-based products are available already packaged and branded, or sold in bulk to customers who repackage them for private-label sale. Customers include distributors, retailers, and multi-level marketing companies. Its services include product formulation, sample runs, and product testing. Chairman and CEO Pailla Reddy holds a majority of the company.

NBTY, Inc. was founded in 1971 and is based in Ronkonkoma, New York. NBTY, Inc. manufactures, markets, and retails nutritional supplements in the United States and worldwide. It offers various products, including vitamins, minerals, and sports and other nutritional supplements; food products, such as fruits, nuts, and confectionery products; and personal care products. The company markets approximately 25,000 products under the brands Nature's Bounty, Ester-C, Solgar, MET-Rx, American Health, Osteo Bi-Flex, Flex-A-Min, SISU, Knox, Sundown, Rexall, Pure Protein, Body Fortress, WORLDWIDE Sport Nutrition, Natural Wealth, Puritan's Pride, Holland & Barrett, GNC (UK), Physiologics, Le Naturiste, De Tuinen, Julian Graves, and Vitamin World. It primarily sells its products to mass merchandisers, club stores, drug store chains and supermarkets, wholesale clubs, independent pharmacies, health food stores, health food store wholesalers, the military and other retailers. The company also sells its products through mail order catalog and the Internet. As of September 30, 2009, it operated 442 Vitamin World stores in the United States; 86 Le Naturiste stores in Canada; 537 Holland and Barrett stores in Europe; 351 Julian Graves stores and 31 GNC (UK) stores in the United Kingdom; 80 De Tuinen stores in the Netherlands; 24 Nature's Way stores in Ireland; and 9 franchise Holland and Barrett stores in South Africa.

Idera Pharmaceuticals, Inc. company was founded in 1989 and is based in Cambridge, Massachusetts. Idera Pharmaceuticals, Inc., a biotechnology company, discovers and develops DNA- and RNA-based drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. The company designs and creates proprietary Toll-Like Receptors (TLR) to modulate immune responses, including TLR agonist, a compound that stimulates an immune response through the targeted TLR; and TLR antagonist, a compound that blocks activation of an immune response through the targeted TLR. Its drug candidates include IMO-2125, a TLR9 agonist, which is in Phase 1 clinical trial for hepatitis C virus infection; and TLR7, 8, and 9 agonists that are in research stage for viral diseases. The company also develops IMO-3100, a dual TLR7/TLR9 antagonist, which is in preclinical development stage for autoimmune and inflammatory diseases, such as lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis.In addition, its drug candidates also comprise TLR7 and TLR8 agonists that are in research stage for solid tumor cancers. The company has a licensing and collaboration agreement with Merck KGaA to research, develop, and commercialize TLR9 agonists for the treatment of cancer, excluding cancer vaccines; a license and research collaboration agreement with Merck & Co., Inc. to research, develop, and commercialize therapeutic and prophylactic vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer's disease; and a research collaboration and option agreement, and a license, development, and commercialization agreement with Novartis International Pharmaceutical, Ltd. to discover, develop, and commercialize TLR9 agonists for the treatment of asthma and allergies.

ReNew Life Formulas, Inc. was founded by President Brenda Watson in 1997. ReNew Life Formulas aims to make a clean sweep of clogged colons and hasten one's pace to the restroom. ReNew Life Formulas company makes and wholesales dietary supplements and therapeutic products for digestive health. Its products CleanseSMART, ParaGONE, CandiGONE, and Liver Detox are a few of the products offered as part of its cleansing and detoxification line. Its digestive support products include fish oils, probiotics, and digestive enzymes. The company also makes products tailored for kids. ReNew Life Formulas sells its products through health food stores and online retailers in the US and Canada.

Noramco, a subsidiary of healthcare giant Johnson & Johnson, makes active pharmaceutical ingredients used in the medications and medical devices made by Johnson and Johnson subsidiaries (including Ortho-McNeil Pharmaceutical, Janssen, and Ethicon), as well as third parties. The company was founded in 1979 to support the manufacture of Ortho-McNeil's Tylenol with codeine product line. It is one of a very few US companies allowed by the DEA to import such controlled substances as opium for use in painkillers like oxycodone and morphine. Noramco operates two manufacturing facilities in Athens, Georgia, and Wilmington, Delaware.

Oxford Gene Technology Ltd. owned company was founded in 1995 by Professor Sir Edwin Southern. Oxford Gene Technology (OGT) provides microarray products and services that enable clinical research and molecular diagnostics in academic, hospital, and government research laboratories. One of its key business areas, licensing, gives companies access to its intellectual property that covers microarrays, genomics, and electrochemistry. OGT's research focuses on developing novel microarray technologies for new applications such as drug discovery and disease diagnosis.

Dr. Reddy’s Laboratories Limited (Dr. Reddy’s) is a global pharmaceutical company. The Company operates in three segments: Pharmaceutical Services and Active Ingredients (PSAI), which includes active pharmaceutical ingredients and intermediaries, which are the principal ingredients for finished pharmaceutical products; Global Generics, which consists of finished pharmaceutical products ready for consumption by the patient, and Proprietary Products, which involves the discovery of new chemical entities for subsequent commercialization and out-licensing. Dr. Reddy’s is vertically integrated and uses its pharmaceutical ingredients and intermediates in its own finished dosage products. The Company conducts basic research mainly in the areas of metabolic disorders, cardiovascular diseases and bacterial infection. On July 30, 2008, it acquired 85.69% interest in Perlecan Pharma Private Limited (Perlecan Pharma). Subsequently Perlecan Pharma became a wholly owned subsidiary of the Company.

Ranbaxy Laboratories Limited company is India's largest drug manufacturer, as well as a top global generics producer. Anti-infectives amoxycillin and ciprofloxacin, and cardio drug simvastatin are among Ranbaxy's top sellers; all come in several administration forms. The company also addresses gastrointestinal, musculoskeletal, and central nervous system disorders, as well as diabetes, pain, allergies, and HIV/AIDS. Its R&D focus includes new forms of existing drugs and metabolic disease treatments. The company also has a groundbreaking anti-malarial candidate in late-phase trials. Japanese drugmaker Daiichi Sankyo owns a controlling stake in Ranbaxy.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.